Bayer and Evotec have announced an expansion of their strategic collaboration towards innovative precision therapies for cardiovascular disease (CVD).

The collaboration aims to identify and validate new targets, with the aim of building a portfolio of precision cardiology therapies using human induced pluripotent stem cells (iPSCs).

Under the terms of the agreement, both companies will contribute to the establishment of drug targets and a comprehensive set of technology platforms for the development of innovative therapeutic options.

' We remain committed to developing innovative therapies for patients in need and tackling the heavy burden of cardiovascular disease. said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer's Pharmaceuticals Division.

Copyright (c) 2024 All rights reserved.